We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
First NCFB patient dosed in Phase IIa study of RESP-X
Potential first-in-class anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory patients with chronic Pseudomonas aeruginosa (Pa) colonisation.
Infex invites you to Alderley Park’s 10th Anniversary SciTech Extravaganza
Come and join us in Glasshouse at Alderley Park for an interactive and inspiring day of science and technology fun, in collaboration with The Royal Institution (RI).
Infex to present RESP-X Phase I data at ERS Congress
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory patients with chronic Pseudomonas aeruginosa (Pa) colonisation.
Latest News
First NCFB patient dosed in Phase IIa study of RESP-X
Potential first-in-class anti-virulence antibody drug to reduce the frequency of…
Infex invites you to Alderley Park’s 10th Anniversary SciTech Extravaganza
Come and join us in Glasshouse at Alderley Park for an interactive and inspiring day of…
Infex to present RESP-X Phase I data at ERS Congress
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of…
Infex strengthens its senior leadership team
Appointment of Director of Clinical Programmes and changes to senior management team
Infex webinar – broader pipeline and growth strategy
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the company's…
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
Infex Therapeutics, a leading anti-infectives specialist, welcomes the UK government’s…
Infex to present webinar on broader pipeline and growth strategy
Infex Therapeutics, a leading anti-infectives specialist, announces it will be holding a…
Webinar on Infex’s Phase II lead respiratory drug, RESP-X
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with our lead…